AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22277663
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg bolus + 16 mg in PCA)
Trial: 18496393
Drug: Rectoanal inhibitory
RxNorm normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectoanal inhibitory reflex (RAIR) assessment with balloon distention (10 to 50 mL) in constipation patients
Trial: 12180224
Drug: Antibacterial prophylaxis
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial prophylaxis (1 g i.v. injection of cephradine at induction of anaesthesia) (Group C)
Trial: 2015177
Drug: Yohimbine (22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (22 mg)
Trial: 2015177
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clonidine and yohimbine
Trial: 31277532
Drug: Acupotomy-injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupotomy-injection technique with targeted three-point
Trial: 31277532
Drug: Small needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small needle knife therapy
Trial: 22152089
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol (MF/F) 200/10 μg via metered-dose inhaler (MDI) BID
Trial: 22152089
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (FP/S) 250/50 μg via dry powder inhaler (DPI) BID
Trial: 19776771
Drug: Anti-aggregation with
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-aggregation with dipyridamole and aspirin
Trial: 15448954
Drug: Glucocorticoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid therapy (GCC)
Trial: 8591949
Drug: Combination regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin
Trial: 8591949
Drug: Chloroquine monotherapy
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine monotherapy (45 mg/kg over 3 days)
Trial: 2474057
Drug: LNH-84 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNH-84 regimen (ACVB) comprising doxorubicin 75 mg/m2, cyclophosphamide 1200 mg/m2, vindesine 2 mg/m2 x 2, bleomycin 10 mg x 2, prednisolone 60 mg/m2 x 5, followed by high-dose methotrexate, ifosfamide, etoposide, asparaginase, and cytarabine, with late intensification using AraCVmB.
Trial: 31282921
Drug: Adjunctive corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive corticosteroids (prednisolone acetate, 50 mg/d for 7 days) and other bundled interventions
Trial: 31282921
Drug: Adjunctive corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive corticosteroids (intervention group)
Trial: 23286834
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d of HMB-FA
Trial: 1505537
Drug: 4D taper
RxNorm normalized name: CAPER BERRY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4D taper (4 days; n = 7)
Trial: 1505537
Drug: 8D taper
RxNorm normalized name: CAPER BERRY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8D taper (8 days; n = 6)
Trial: 1505537
Drug: NOTAPER (non-taper,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOTAPER (non-taper, continued training; n = 6)
Trial: 6833021
Drug: Colestipol hydrochloride,
RxNorm normalized name: Colestipol Hydrochloride, Micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol hydrochloride, 5 grams qid during therapy
Trial: 6833021
Drug: Diphenoxylate hydrochloride
RxNorm normalized name: Diphenoxylate Hydrochloride
DrugBank: Diphenoxylate (DB01081)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diphenoxylate hydrochloride and atropine sulfate, 2.5‐20 mg per day (control) if diarrhea occurred
Trial: 24215716
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of recombinant human follicle-stimulating hormone (rhFSH) 300 IU on alternate days for ≥4 months
Trial: 17822466
Drug: Early intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention using vacuum erection device (VED) starting 1 month after RP, daily for 10 min/day for 5 months.
Trial: 12035874
Drug: Long-acting calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting calcium channel blockers (CCBs) such as nifedipine GITS, nitrendipine, and diltiazem
Trial: 9697672
Drug: Synthetic urodilatin
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic urodilatin (URO) infusion at a low dose of 20 ng x kg(‐1) x min(‐1) for 60 minutes
Trial: 10586205
Drug: rHuEpo +
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo + G‐CSF (1 microg/kg) three times a week for 8 weeks (added if PR or NR after rHuEpo)
Trial: 10586205
Drug: rHuEpo administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rHuEpo administration
Trial: 2518952
Drug: Fragmented virus
RxNorm normalized name: palmitoyl fragment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmented virus vaccine
Trial: 750603
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (2 g)
Trial: 25201903
Drug: LigaSure group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LigaSure group (Subgroup g: 3 bars-power levels/1 frequency application)
Trial: 16963041
Drug: Fasting glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose, fasting insulin, body mass index, and free T in patients with PCOS
Trial: 27048405
Drug: PCT-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided therapy
Trial: 23702257
Drug: 9.6% carbohydrate‐caffeine‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.6% carbohydrate‐caffeine‐electrolyte solution with carbohydrate‐electrolyte gels (H‐CHO)
Trial: 23702257
Drug: 5.6% carbohydrate‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.6% carbohydrate‐electrolyte solution with electrolyte gels (CHO)
Trial: 23702257
Drug: Electrolyte solution
RxNorm normalized name: electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrolyte solution and electrolyte gels (PL)
Trial: 22184384
Drug: XP (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP (capecitabine 2,000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Trial: 22184384
Drug: XP/XRT/XP (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP/XRT/XP (two cycles of XP followed by 45-Gy XRT with capecitabine 1,650 mg/m2 per day for 5 weeks and two cycles of XP)
Trial: 19883407
Drug: Scheduled maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled maintenance treatment with infliximab (5 mg/kg)
Trial: 18762502
Drug: Recurrent antichlamydial
RxNorm normalized name: Acacia decurrens extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recurrent antichlamydial treatments
Trial: 8749726
Drug: Desipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine (150 mg, p.o.)
Trial: 8749726
Drug: Amantadine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (300 mg, p.o.)
Trial: 8749726
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg, p.o.)
Trial: 2049233
Drug: Nifedipine, sparteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, sparteine and phenytoin administered as a 'cocktail'
Trial: 2049233
Drug: Single substrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single substrate administration of nifedipine, sparteine and phenytoin
Trial: 28337660
Drug: Perioperative ECF
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative ECF chemotherapy alone
Trial: 28337660
Drug: Perioperative ECF
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative ECF chemotherapy with preoperative chemoradiation
Trial: 15523532
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during acute hemiplegia (Group A)
Trial: 15523532
Drug: Functional Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electrical Therapy (FET), applied 30 min daily for 3 weeks, during chronic hemiplegia (Group B)
Trial: 7710234
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous fentanyl
Trial: 2901267
Drug: Terazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (1 to 40 mg daily for 3 weeks to 56 months)
Trial: 2901267
Drug: Terazosin in
RxNorm normalized name: Product containing terazosin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin in combination with other antihypertensive agents
Trial: 26922379
Drug: Bacillus coagulans
RxNorm normalized name: Bacillus coagulans
DrugBank: Bacillus coagulans (DB19246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus coagulans MTCC 5856 tablet containing 2 × 10(9) cfu/day for 90 days
Trial: 25693859
Drug: LCZ696 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 100 mg (with optional titration to 200 and 400 mg)
Trial: 23617229
Drug: Bimatoprost 0.03%
RxNorm normalized name: BIMATOPROST 0.03% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bimatoprost 0.03% ophthalmic solution applied daily for 9 months
Trial: 17601603
Drug: GnRH‐a/chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH‐a/chemotherapy
Trial: 8860064
Drug: Nisoldipine 20
RxNorm normalized name: nisoldipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine 20 mg twice daily
Trial: 1298143
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg Bezafibrate retard
Trial: 1298143
Drug: 20 to
RxNorm normalized name: Vite20 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 to 80 mg Lovastatin
Trial: 31239111
Drug: Solifenacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5 mg per day) for 3 months
Trial: 31239111
Drug: Solifenacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5 mg per day) for 6 months
Trial: 15094269
Drug: Nevirapine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine (400 mg) and efavirenz (800 mg) once daily
Trial: 15094269
Drug: Nevirapine once
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine once daily
Trial: 15094269
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nevirapine and efavirenz
Trial: 7909285
Drug: Salmeterol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (all doses)
Trial: 3281702
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (Protocol D)
Trial: 3281702
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone, metoclopramide and diphenhydramine (Protocol DMD)
Trial: 31028669
Drug: Other second-generation
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other second-generation BTK inhibitors (acalabrutinib, zanubrutinib, tirabrutinib)
Trial: 31028669
Drug: Reversible BTK
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversible BTK inhibitors (vecabrutinib, LOXO-305)
Trial: 31028669
Drug: Non-selective reversible
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective reversible BTK inhibitors (ARQ-531)
Trial: 21531174
Drug: Gatifloxacin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin (10 mg/kg once a day for 7 days)
Trial: 21531174
Drug: Chloramphenicol (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (75 mg/kg per day in four divided doses for 14 days)
Trial: 17136556
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (e.g., natalizumab)
Trial: 9342766
Drug: High-dose hypericum
RxNorm normalized name: Hypericum oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hypericum extract
Trial: 3513716
Drug: Desmopressin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (20 micrograms intranasal nightly for three months)
Trial: 24911028
Drug: Buspirone titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone titrated to 60 mg/d
Trial: 18585835
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 2 g/d for 12 months
Trial: 25533307
Drug: Close Rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Close Rectal Dissection (CRD)
Trial: 23658423
Drug: 0.45 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 g/d 20:5n3 and 22:6n3 (1.51:1)
Trial: 23658423
Drug: 0.9 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g/d 20:5n3 and 22:6n3 (1.51:1)
Trial: 23658423
Drug: 1.8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/d 20:5n3 and 22:6n3 (1.51:1)
Trial: 21874260
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of branched-chain amino acids (BCAA; 12 g/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Trial: 21874260
Drug: ACE-I (perindopril;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-I (perindopril; 4 mg/day)
Trial: 15257378
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g per day for 2 or 3 weeks
Trial: 12716812
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg o.d.)
Trial: 9988834
Drug: Estrostep (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrostep (20 microg ethinyl estradiol on days 1-5, 30 microg on days 6-12, 35 microg on days 13-21, and 1 mg norethindrone acetate throughout the cycle)
Trial: 9988834
Drug: 30-microg ethinyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30-microg ethinyl estradiol monophasic control drug
Trial: 9988834
Drug: Triphasic control
RxNorm normalized name: Tribasic Calcium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic control drug
Trial: 7191315
Drug: Acemetacin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (90 mg daily)
Trial: 7191315
Drug: Tolmetin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolmetin (600 mg daily)
Trial: 31915064
Drug: Morita therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morita therapy
Trial: 30203308
Drug: Enhanced version
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced version of parent-implemented Early Start Denver Model (P-ESDM) with motivational interviewing, multimodal learning tools, and weekly 1.5-h home visits for 12 weeks.
Trial: 30203308
Drug: Basic model
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic model of parent-implemented Early Start Denver Model (P-ESDM) with 1.5 h of clinic-based parent coaching weekly for 12 weeks.
Trial: 25156040
Drug: Low-dose beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose beta-carotene (10 mg day(-1)) and vitamin C (500 mg day(-1))
Trial: 25156040
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 mg day(-1) of vitamin C)
Trial: 25156040
Drug: Low-dose beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose beta-carotene and vitamin C
Trial: 11352955
Drug: HD-MVAC (high-dose-intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HD-MVAC (high-dose-intensity chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin plus granulocyte colony-stimulating factor)
Trial: 11352955
Drug: MVAC (classic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVAC (classic chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin)
Trial: 8004882
Drug: Nisoldipine and
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine and Propranolol (10 mg twice daily and 80 mg twice daily respectively)
Trial: 23097272
Drug: Iron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron (50 mg) plus DHA/EPA (420/80 mg)
Trial: 16960468
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dapoxetine and 20 mg paroxetine
Trial: 9425966
Drug: Subarachnoid lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid lidocaine (75 mg)
Trial: 9425966
Drug: Subarachnoid lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid lidocaine (75 mg) in women
Trial: 27639604
Drug: Cabergoline 0.5mg
RxNorm normalized name: CABERGOLINE 0.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.5mg weekly for three months
Trial: 20067426
Drug: Anthelminthic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthelminthic treatment
Trial: 18717802
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1)) as an adjunct to TIVA (propofol and remifentanil)
Trial: 18717802
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 microg x kg(‐1) over 20 min followed by an infusion of 0.5 microg x kg(‐1) x h(‐1))
Trial: 10343216
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg hyoscyamine sulfate intravenous (n = 57)
Trial: 22146757
Drug: Upstream use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upstream use of clotinab with 600-mg clopidogrel pretreatment
Trial: 22146757
Drug: Provisional use
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provisional use of clotinab with 600-mg clopidogrel pretreatment
Trial: 20648601
Drug: Overlap of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overlap of LAM and ADV for 3 months followed by ADV monotherapy
Trial: 17466071
Drug: Topical honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical honey along with intralesional injection of glucantime
Trial: 17466071
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of glucantime alone
Trial: 14964629
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% applied twice daily with overnight occlusion
Trial: 11313170
Drug: L-758,298 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-758,298 (60 or 100 mg)
Trial: 11313170
Drug: Ondansetron (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (32 mg)
Trial: 8198929
Drug: Locally applied
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally applied morphine at 100 ng ml‐1
Trial: 8198929
Drug: Locally applied
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally applied morphine at 100 micrograms ml‐1
Trial: 3332675
Drug: Acyclovir 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 3% ointment and vidarabine 3% ointment
Trial: 3332675
Drug: Acyclovir 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 3% ointment and placebo
Trial: 22666758
Drug: Injection (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection (control group)
Trial: 19913781
Drug: Online cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online cognitive behavioral therapy (CBT)